Cardiff Oncology, Inc.
NASDAQ:CRDF
Overview | Financials
Company Name | Cardiff Oncology, Inc. |
Symbol | CRDF |
Currency | USD |
Price | 3.92 |
Market Cap | 260,752,128 |
Dividend Yield | 0% |
52-week-range | 1.41 - 6.42 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Mark Erlander Ph.D. |
Website | https://www.cardiffoncology.com |
An error occurred while fetching data.
About Cardiff Oncology, Inc.
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias;
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD